Tech Company Financing Transactions
OptiNose Funding Round
OptiNose, based in Yardley, secured $37 million from Fidelity Management & Research Company, Avista and private investors.
Transaction Overview
Company Name
Announced On
4/10/2017
Transaction Type
Venture Equity
Amount
$37,000,000
Round
Series D
Investors
Fidelity Management & Research Company (Lead Investor)
Proceeds Purpose
OptiNose will use the additional capital to fund commercial readiness for the launch of its lead product candidate, OPN-375, in the United States.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
1020 Stony Hill Rd. 300
Yardley, PA 19067
USA
Yardley, PA 19067
USA
Phone
Website
Email Address
Overview
Optinose (Nasdaq: OPtN) creates drug delivery technologies that in essence make good drugs better. We hope to accomplish this by taking aim at one of the healthcare industry's greatest challenges: to efficiently and reliably deliver drugs to targeted, hard to reach areas of the body in order to treat medical conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Miller
Chief Operating Officer
Ramy Mahmoud
Chief Scientific Officer
Per Djupesland
VP - Bus. Development
John Messina
VP - Finance
Michele Janis
VP - Regulatory Affairs
Ramona Lloyd
Browse more venture capital transactions:
Prev: 4/10/2017: Sphero venture capital transaction
Next: 4/10/2017: Kymeta venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs